Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors.
Open Access
- 20 February 1996
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 93 (4) , 1648-1653
- https://doi.org/10.1073/pnas.93.4.1648
Abstract
The observed in vitro and in vivo benefit of combination treatment with anti-human immunodeficiency virus (HIV) agents prompted us to examine the potential of resistance development when two protease inhibitors are used concurrently. Recombinant HIV-1 (NL4-3) proteases containing combined resistance mutations associated with BMS-186318 and A-77003 (or saquinavir) were either inactive or had impaired enzyme activity. Subsequent construction of HIV-1 (NL4-3) proviral clones containing the same mutations yielded viruses that were severely impaired in growth or nonviable, confirming that combination therapy may be advantageous. However, passage of BMS-186318-resistant HIV-1 (RF) in the presence of either saquinavir or SC52151, which represented sequential drug treatment, produced viable viruses resistant to both BMS-186318 and the second compound. The predominant breakthrough virus contained the G48V/A71T/V82A protease mutations. The clone-purified RF (G48V/A71T/V82A) virus, unlike the corresponding defective NL4-3 triple mutant, grew well and displayed cross-resistance to four distinct protease inhibitors. Chimeric virus and in vitro mutagenesis studies indicated that the RF-specific protease sequence, specifically the Ile at residue 10, enabled the NL4-3 strain with the triple mutant to grow. Our results clearly indicate that viral genetic background will play a key role in determining whether cross-resistance variants will arise.Keywords
This publication has 25 references indexed in Scilit:
- In vivo emergence of HIV-1 variants resistant to multiple protease inhibitorsNature, 1995
- Characterization of human immunodeficiency virus type 1 mutantswith decreased sensitivity to proteinase inhibitor Ro 31-8959Virology, 1995
- Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infectionNature, 1995
- Viral dynamics in human immunodeficiency virus type 1 infectionNature, 1995
- L-735,524: The Design of a Potent and Orally Bioavailable HIV Protease InhibitorJournal of Medicinal Chemistry, 1994
- Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease.Proceedings of the National Academy of Sciences, 1994
- Amino Diol HIV Protease Inhibitors. 1. Design, Synthesis, and Preliminary SARJournal of Medicinal Chemistry, 1994
- L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor.Proceedings of the National Academy of Sciences, 1994
- Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitroAntimicrobial Agents and Chemotherapy, 1994
- Issues in combination antiretroviral therapy: a review.1994